[HTML][HTML] Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
Genome medicine, 2019•Springer
Background Although mutated HLA ligands are considered ideal cancer-specific
immunotherapy targets, evidence for their presentation is lacking in hepatocellular
carcinomas (HCCs). Employing a unique multi-omics approach comprising a neoepitope
identification pipeline, we assessed exome-derived mutations naturally presented as HLA
class I ligands in HCCs. Methods In-depth multi-omics analyses included whole exome and
transcriptome sequencing to define individual patient-specific search spaces of neoepitope …
immunotherapy targets, evidence for their presentation is lacking in hepatocellular
carcinomas (HCCs). Employing a unique multi-omics approach comprising a neoepitope
identification pipeline, we assessed exome-derived mutations naturally presented as HLA
class I ligands in HCCs. Methods In-depth multi-omics analyses included whole exome and
transcriptome sequencing to define individual patient-specific search spaces of neoepitope …
Background
Although mutated HLA ligands are considered ideal cancer-specific immunotherapy targets, evidence for their presentation is lacking in hepatocellular carcinomas (HCCs). Employing a unique multi-omics approach comprising a neoepitope identification pipeline, we assessed exome-derived mutations naturally presented as HLA class I ligands in HCCs.
Methods
In-depth multi-omics analyses included whole exome and transcriptome sequencing to define individual patient-specific search spaces of neoepitope candidates. Evidence for the natural presentation of mutated HLA ligands was investigated through an in silico pipeline integrating proteome and HLA ligandome profiling data.
Results
The approach was successfully validated in a state-of-the-art dataset from malignant melanoma, and despite multi-omics evidence for somatic mutations, mutated naturally presented HLA ligands remained elusive in HCCs. An analysis of extensive cancer datasets confirmed fundamental differences of tumor mutational burden in HCC and malignant melanoma, challenging the notion that exome-derived mutations contribute relevantly to the expectable neoepitope pool in malignancies with only few mutations.
Conclusions
This study suggests that exome-derived mutated HLA ligands appear to be rarely presented in HCCs, inter alia resulting from a low mutational burden as compared to other malignancies such as malignant melanoma. Our results therefore demand widening the target scope for personalized immunotherapy beyond this limited range of mutated neoepitopes, particularly for malignancies with similar or lower mutational burden.
Springer